Perrigo Co. Plc (PRGO)

49.38
NYSE : Health Technology
Prev Close 48.04
Day Low/High 48.19 / 49.51
52 Wk Low/High 36.28 / 64.63
Avg Volume 1.06M
Exchange NYSE
Shares Outstanding 136.11M
Market Cap 6.54B
EPS 0.90
P/E Ratio 26.69
Div & Yield 0.84 (1.65%)

Latest News

Perrigo Announces Quarterly Dividend

Perrigo Announces Quarterly Dividend

DUBLIN, Nov. 4, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.

Perrigo Company Plc Issues Voluntary Worldwide Recall Of Ranitidine Due To Possible Presence Of Impurity, N-nitrosodimethylamine (NDMA) Impurity In The Product

Perrigo Company Plc Issues Voluntary Worldwide Recall Of Ranitidine Due To Possible Presence Of Impurity, N-nitrosodimethylamine (NDMA) Impurity In The Product

DUBLIN, Oct. 23, 2019 /PRNewswire/ -- As a precautionary measure, Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes).

Perrigo Announces Third Quarter Calendar Year 2019 Earnings Date

Perrigo Announces Third Quarter Calendar Year 2019 Earnings Date

DUBLIN, Oct. 15, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019.

Perrigo® Hosts 175 West Michigan Students For Manufacturing Week Celebration

Perrigo® Hosts 175 West Michigan Students For Manufacturing Week Celebration

Students from Seven Area High Schools Spent the Day at Perrigo's Allegan, Mich. Plants: Manager from Valued Customer, Walmart, Demonstrated Perrigo Products' Retail Journey

Perrigo Announces The Relaunch Of The AB Rated Generic Version Of Transderm Scop® 1.5 MG

Perrigo Announces The Relaunch Of The AB Rated Generic Version Of Transderm Scop® 1.5 MG

DUBLIN, Oct. 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop ® (scopolamine 1.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARTX, DOOR, GMS, LEG, LIVE, NTWK, PRGO, SNX, WDR Downgrades: CCR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Perrigo Advances Consumer Self-Care Growth Strategy With Acquisition Of Prevacid®24hr

Perrigo Advances Consumer Self-Care Growth Strategy With Acquisition Of Prevacid®24hr

- Expands U.S. OTC market and gastrointestinal category leadership positions

Ex-Dividend Reminder: Perrigo Company, Mesa Laboratories And EPR Properties

Ex-Dividend Reminder: Perrigo Company, Mesa Laboratories And EPR Properties

Looking at the universe of stocks we cover at Dividend Channel, on 8/29/19, Perrigo Company plc , Mesa Laboratories, Inc. , and EPR Properties will all trade ex-dividend for their respective upcoming dividends.

Perrigo To Present At Upcoming Investor Conferences

Perrigo To Present At Upcoming Investor Conferences

DUBLIN, Aug. 22, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S.

Perrigo Announces Patent Litigation Settlement For The Generic Version Of Nascobal® Nasal Spray

Perrigo Announces Patent Litigation Settlement For The Generic Version Of Nascobal® Nasal Spray

DUBLIN, Aug. 21, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Nascobal ®  (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals Inc.

Defy False Market Fears: Cramer's 'Mad Money' Recap (Thursday 8/8/19)

Defy False Market Fears: Cramer's 'Mad Money' Recap (Thursday 8/8/19)

Jim Cramer says investors must resist the siren song of panic, and he puts interest rates, tariffs, currency and earnings in perspective.

Perrigo Beats Second-Quarter Estimates but Stock Tumbles

Perrigo Beats Second-Quarter Estimates but Stock Tumbles

Perrigo is falling despite beating Wall Street's second-quarter earnings and revenue expectations.

Perrigo Company Plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation

Perrigo Company Plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation

DUBLIN, Aug. 8, 2019 /PRNewswire/ -- GAAP ("reported") net sales were $1.

Perrigo Announces Resignation Of Jeffrey C. Smith From Its Board Of Directors

Perrigo Announces Resignation Of Jeffrey C. Smith From Its Board Of Directors

DUBLIN, Aug. 7, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products ™", today announced that Jeffrey C.

Perrigo Announces Quarterly Dividend

Perrigo Announces Quarterly Dividend

DUBLIN, July 31, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.

Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date

Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date

DUBLIN, July 25, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019.

Perrigo Completes Divestiture Of Animal Health Business For $185 Million

Perrigo Completes Divestiture Of Animal Health Business For $185 Million

DUBLIN, July 8, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (NASDAQ: PETQ) for $185 million.

Perrigo Announces FDA Final Approval And Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel

Perrigo Announces FDA Final Approval And Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel

DUBLIN, July 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced its product development partner received final approval from the U.

Perrigo Completes Acquisition Of Ranir, Raises Guidance

Perrigo Completes Acquisition Of Ranir, Raises Guidance

- Advances transformation to a consumer-focused, self-care company

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

INVESTOR ALERT: Monteverde & Associates PC Launches Legal Inquiry Regarding The Acquisition

INVESTOR ALERT: Monteverde & Associates PC Launches Legal Inquiry Regarding The Acquisition

NEW YORK, May 22, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Perrigo Co.

Perrigo Buys Oral Care Company Ranir for $750 Million as Part of New Strategy

Perrigo Buys Oral Care Company Ranir for $750 Million as Part of New Strategy

The all-cash acquisition is part of an effort to expand into an adjacent self-care product category, Perrigo says.

IRS Has Wrong Prescription for Perrigo

IRS Has Wrong Prescription for Perrigo

Perrigo tumbles after announcing that it had received a bill from the IRS for $843 million.

Perrigo Company Becomes #92 Most Shorted S&P 500 Component, Replacing Viacom

Perrigo Company Becomes #92 Most Shorted S&P 500 Component, Replacing Viacom

The most recent short interest data has been released for the 03/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Don't Be a Hero: Cramer's 'Mad Money' Recap (Friday 3/22/19)

Don't Be a Hero: Cramer's 'Mad Money' Recap (Friday 3/22/19)

Jim Cramer says there's so much money being run by computers, stocks are virtually destined to come down in this situation. Here's the game plan.

Axon Enterprise, Perrigo, Merck: 'Mad Money' Lightning Round

Axon Enterprise, Perrigo, Merck: 'Mad Money' Lightning Round

Jim Cramer weighs in on Axon Enterprise, Perrigo, Merck, Alteryx, Enterprise Products Partners and more.

PERRIGO INVESTOR ALERT: Rosen Law Firm Reminds Perrigo Company Plc Investors Of Important March 4, 2019 Deadline In Securities Class Action Lawsuit - PRGO

PERRIGO INVESTOR ALERT: Rosen Law Firm Reminds Perrigo Company Plc Investors Of Important March 4, 2019 Deadline In Securities Class Action Lawsuit - PRGO

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Perrigo Company plc (NYSE: PRGO) from November 8, 2018 through December 20, 2018, inclusive (the "Class Period") of the important March 4, 2019 deadline in the...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Perrigo Company Plc - PRGO

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Perrigo Company Plc - PRGO

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Perrigo Company plc (NYSE:PRGO) from November 8, 2018 through December 20, 2018, inclusive (the "Class Period").

TheStreet Quant Rating: C+ (Hold)